Can visceral fat, insulin resistance, and type 2 diabetes reduce male testosterone availability?

Visceral adiposity, insulin resistance, and type 2 diabetes are major drivers of male endocrine dysfunction, acting through interconnected inflammatory, neuroendocrine, and enzymatic pathways that suppress testosterone availability.

Neuroendocrine and inflammatory suppression

• Cytokine-mediated suppression: Expanded visceral adipose tissue acts as an active endocrine organ, releasing pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β. These circulating cytokines directly impair testicular Leydig cell steroidogenesis, reducing testosterone production at the source.
• HPG axis disruption: Chronic hyperinsulinemia, leptin resistance, and hypothalamic inflammatory signaling suppress kisspeptin-dependent signaling and GnRH neuron pulsatility in the arcuate nucleus. This central defect blunts the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), depriving Leydig cells of the gonadotropic stimulation required for testosterone synthesis.

Enhanced peripheral aromatization

• Upregulation of aromatase: Pro-inflammatory cytokines (TNF-α and IL-6) within inflamed adipose tissue upregulate the transcription of the CYP19A1 gene, which encodes the aromatase enzyme.
• Substrate depletion and negative feedback: Elevated aromatase activity in expanded visceral fat depots accelerates the peripheral conversion of testosterone to estradiol. This process depletes circulating testosterone levels and generates excess estradiol, which exerts further inhibitory negative feedback on the HPG axis, compounding LH suppression.
• The bidirectional cycle: This endocrine disruption establishes a pathological feedback loop, as reduced male testosterone availability subsequently promotes further visceral adiposity, insulin resistance, and type 2 diabetes.

Bottom line

• Metabolic dysfunction suppresses male testosterone through a bidirectional feedback loop involving pro-inflammatory cytokine-driven HPG axis and Leydig cell impairment, alongside accelerated, cytokine-upregulated aromatization of testosterone to estradiol in adipose tissue.